


How subcutaneous administration can help to relieve the burden of breast cancer treatment

The growing burden of breast cancer on healthcare systems and society


Global economic burden of new cases of breast cancer is estimated as **US\$28 billion yearly**¹

Breast cancer is now the most common type of cancer worldwide²




Caring for someone with breast cancer has a significant impact on **financial, work** and **emotional** status⁵

Breast cancer treatment accounts for 12% of total cancer healthcare costs in the EU each year⁴




Productivity losses estimated as **~€3 billion in EU** yearly⁴



Subcutaneous administration of medicines

People with breast cancer can receive some of their treatments via intravenous (IV) infusion (via a drip) or via subcutaneous (SC; below the skin) injection, if available



- IV is associated with long infusion times that may burden patients' lives and healthcare resources⁶



- SC is more convenient for patients and HCPs and requires less pharmaceutical preparation⁷
- SC is an alternative for patients with poor venous access, limits infections problems, and can be performed in an out-patient setting⁷
- SC is preferred by patients, physicians and healthcare providers and is associated with a reduction in healthcare resources⁷



REFERENCES

- Breast cancer in developing countries. *The Lancet*. 2009; 374(9701):1567.
- International Agency for Research on Cancer. GLOBOCAN 2020. [Internet; cited June 2021]. Available from: https://gco.iarc.fr/today/online-analysis-pie?v=2020&mode=cancer&mode_population=continents&population=900&populations=900&key=total&sex=0&cancer=39&type=0&statistic=5&prevalence=0&population_group=0&ages_group%5B%5D=0&ages_group%5B%5D=17&nb_items=7&group_cancer=1&include_nmssc=1&include_nmssc_other=1&half_pie=0&donut=0.
- Forouzanfar MH et al. Breast and cervical cancer in 187 countries between 1980 and 2010: a systematic analysis. *The Lancet*. 2011; 378(9801):1461-84.
- Luengo-Fernandez R et al. Economic burden of cancer across the European Union: a population-based cost analysis. *Lancet Oncol*. 2013;14(12):1165-74.
- Kusi G et al. The experiences of family caregivers living with breast cancer patients in low-and middle-income countries: a systematic review. *Systematic Reviews* 2020;9:165.
- O'Shaughnessy J, et al. Patient (pt) preference for the pertuzumab-trastuzumab fixed-dose combination for subcutaneous use (PH FDC SC) in HER2-positive early breast cancer (EBC): Primary analysis of the open-label, randomised crossover PHranceSCa study. Presented at ESMO, 2020 Sept 19-21. Abstract #165MO.
- Leveque D. Subcutaneous Administration of Anticancer Agents. *Anticancer Research*. 2014;34 (4) 1579-86.